CliCon S.r.l. Health, Economics and Outcomes Research, Ravenna, Italy.
Clin Ther. 2012 Jan;34(1):190-9. doi: 10.1016/j.clinthera.2011.12.011.
Adherence to statin treatment is expected to be associated with health outcomes. Much of the available evidence is derived from studies conducted on selected populations (eg, Medicaid population), on specific cohorts of patients (eg, patients with diabetes mellitus or those who have experienced acute myocardial infarction [AMI]), or with respect to a single outcome (eg, only death or only AMI).
The aim of this study was to evaluate the association between adherence to statin therapy and all-cause mortality and cardiovascular morbidity (AMI and stroke) in an unselected cohort of newly treated patients.
We performed a population-based retrospective cohort study that included adult patients with a first prescription of a statin from January 1, 2004, through December 31, 2006, using data from the administrative databases of the Local Health Unit of Florence in Italy. Adherence to statin treatment was estimated as the proportion of days covered (PDC) by filled prescriptions and classified as low (PDC, 21%-40%), intermediate-low (PDC, 41%-60%), intermediate-high (PDC, 61%-80%), and high (PDC, >80%). Cases with PDC ≤20% were excluded. A Cox regression model was used to investigate the association between adherence to treatment and all-cause mortality and hospitalization for AMI or stroke.
The cohort consisted of 19,232 patients (9823 men and 9409 women) aged 18 to 102 years (mean [SD], 66.5 [11.4] years): 20.1% had been previously hospitalized for cardiovascular events and 17.6% had been treated with hypoglycemic drugs. Adherence to statins was low in 4427 patients (23.0%), intermediate-low in 3117 (16.2%), intermediate-high in 3784 (19.7%), and high in 7904 (41.1%). Lower-adherent patients were younger and had fewer comorbidities compared with higher-adherent patients. In our multivariable analyses, high adherence was significantly associated with decreased risk of all-cause death, AMI, or stroke. Compared with low adherence (hazard ratio [HR] = 1), the risk was lower in intermediate-low adherence (HR = 0.83; 95% confidence interval [CI], 0.71-0.98; P < 0.05) and much lower in intermediate-high (HR = 0.60; 95% CI, 0.51-0.70; P < 0.001) and high adherence (HR = 0.61; 95% CI, 0.54-0.71; P < 0.001).
In this Italian cohort of newly treated patients, suboptimal adherence to statins occurred in a substantial proportion of patients and was associated with increased risk of adverse health outcomes.
他汀类药物治疗的依从性预计与健康结果相关。现有证据主要来自于对选定人群(例如医疗补助人群)、特定患者队列(例如患有糖尿病或经历过急性心肌梗死[AMI]的患者)或特定单一结果(例如,仅死亡或仅 AMI)进行的研究。
本研究旨在评估在未经选择的新治疗患者队列中,他汀类药物治疗的依从性与全因死亡率和心血管发病率(AMI 和中风)之间的关联。
我们使用意大利佛罗伦萨地方卫生单位的行政数据库进行了一项基于人群的回顾性队列研究,该研究纳入了 2004 年 1 月 1 日至 2006 年 12 月 31 日期间首次开具他汀类药物处方的成年患者。他汀类药物治疗的依从性通过已填写处方的天数占比(PDC)来估计,并分为低(PDC,21%-40%)、中低(PDC,41%-60%)、中高(PDC,61%-80%)和高(PDC,>80%)。PDC≤20%的病例被排除在外。使用 Cox 回归模型研究治疗依从性与全因死亡率和因 AMI 或中风住院之间的关联。
该队列由 19232 名年龄在 18 至 102 岁(平均[标准差],66.5[11.4]岁)的患者组成:20.1%的患者曾因心血管事件住院治疗,17.6%的患者曾接受过降血糖药物治疗。4427 名患者(23.0%)的他汀类药物依从性低,3117 名患者(16.2%)的依从性为中低,3784 名患者(19.7%)的依从性为中高,7904 名患者(41.1%)的依从性高。与高依从性患者相比,低依从性患者年龄更小,合并症更少。在我们的多变量分析中,高依从性与全因死亡、AMI 或中风的风险降低显著相关。与低依从性(风险比[HR] = 1)相比,中低依从性(HR = 0.83;95%置信区间[CI],0.71-0.98;P < 0.05)和中高依从性(HR = 0.60;95% CI,0.51-0.70;P < 0.001)的风险更低,高依从性(HR = 0.61;95% CI,0.54-0.71;P < 0.001)的风险更低。
在意大利这个新治疗患者队列中,相当一部分患者他汀类药物治疗的依从性并不理想,且与不良健康结果的风险增加相关。